The most comprehensive whole exome panel that covers the target regions of all major WES panels in the market. With our proprietary technologies, we provide industry-leading performance and efficiency with complete BI solution.
View Detail >
Hybridization-based target enrichment panel with our intrinsic probe design, rebalancing, and molecular barcode technologies to efficiently analyze not only hard-to-capture areas but also challenging samples, such as damaged DNA or RNA.
View Detail >
End-to-end customized target enrichment panel with assay optimization, validation and even complete BI support. Over 1,000 custom panels developed world-wide. White-labeled customized product for business expansion also available.
View Detail >
The most comprehensive whole exome panel that covers the target regions of all major WES panels in the market. With our proprietary technologies, we provide industry-leading performance and efficiency with complete BI solution.
View Detail >
The most comprehensive whole exome panel that covers the target regions of all major WES panels in the market. With our proprietary technologies, we provide industry-leading performance and efficiency with complete BI solution.
View Detail >
End-to-end customized target enrichment panel with assay optimization, validation and even complete BI support. Over 1,000 custom panels developed world-wide. White-labeled customized product for business expansion also available.
View Detail >
Providing NGS-based diagnostics solutions for biopharma companies. Celemics can develop and deliver a flexible customization and commercialization services while maintaining the market-leading performance for our clients interested in clinical and companion diagnostics.
View Detail >
Tailored-fit customized assay development from designing to validation run; including not only the custom panel design but also species-specific or sequencer-specific blockers, followed by reagent conditioning to optimize the individual experiment and sequencer.
View Detail >
The most comprehensive whole exome panel that covers the target regions of all major WES panels in the market. With our proprietary technologies, we provide industry-leading performance and efficiency with complete BI solution.
View Detail >
Find useful information, insights and tools for your Celemics’ products and services
View Detail >
Explore the most up-to-date publications featuring Celemics’ products and services
View Detail >
Sharing interesting stories about the world of NGS and how Celemics delivers the innovative NGS solutions to the world of science.
View Detail >
Explore a diverse range of engaging video content, from fascinating experiments showcasing cutting-edge research to heartfelt customer testimonials.
View Detail >
Find useful information, insights and tools for your Celemics’ products and services
View Detail >
Stay up-to-date with the latest updates on our activities, events and achievements
View Detail >
Let’s change the NGS market together – our global presence and partners world-wide
View Detail >
Waiting for your experience with Celemics, an innovative leader in NGS industry
View Detail >Liquid Biopsy
Annals of Laboratory Medicine Identification of potential genomic alterations using pan-cancer cell-free DNA next-generation sequencing in patients with gastric cancer Kim B, Kim Y, Cho JY, Lee KA. Identification of…
Translational Lung Cancer Research Predicting disease recurrence in limited disease small cell lung cancer using cell-free DNA-based mutation and fragmentome analyses Park S, Kang J-K, Lee N, Lee S-H, Kim…
Cancer Research and Treatment Analytical and Clinical Validation of a Highly Sensitive NGS-Based ctDNA Assay with Real-World Concordance in NSCLC Yi H, Youk J, Lim Y, Roh H, Roh D,…
Experimental & Molecular Medicine Cancer signature ensemble integrating cfDNA methylation, copy number, and fragmentation facilitates multi-cancer early detection Kim SY, Jeong S, Lee W, Jeon Y, Kim Y-J, Park S,…
Cancers Practical Utility of Liquid Biopsies for Evaluating Genomic Alterations in Castration-Resistant Prostate Cancer Jeong S-H, Kyung D, Yuk HD, Jeong CW, Lee W, Yoon J-K, et al. Practical utility…
British Journal of Cancer Personalised circulating tumour DNA assay with large-scale mutation coverage for sensitive minimal residual disease detection in colorectal cancer Ryoo S-B, Heo S, Lim Y, Lee W,…
Clin Chem Analytical and Clinical Validation of Cell-Free Circulating Tumor DNA Assay for the Estimation of Tumor Mutational Burden Lee KS, Seo J, Lee CK, Shin S, Choi Z, Min…
Br J Cancer Dynamic changes in longitudinal circulating tumour DNA profile during metastatic colorectal cancer treatment Kim S, Lim Y, Kang JK, Kim HP, Roh H, Kim SY, et al.…
World Journal of Clinical Cases Detection of EGFR-SEPT14 fusion in cell-free DNA of a patient with advanced gastric cancer: A case report Kim B, Kim Y, Park I, Cho JY,…
Investigative and clinical urology Genomic mutation profiling using liquid biopsy in Korean patients with prostate cancer: Circulating tumor DNA mutation predicts the development of castration resistance </h4 > Yu J,…
